Astellas acquires a unique screening platform to help develop mitochondrial disease drugs.

On April 21st local time, Astellas announced the acquisition of Nanna Therapeutics Limited, a British biotech company, with plans to apply Nanna's advanced compound screening technology to early development of drugs for mitochondrial-related diseases.
it is understood that the acquisition, through its UK subsidiary, was carried out by Astellas to acquire all of Nanna's outstanding share capital.
Astellas paid a bid of 12 million pounds, and Nanna's shareholders are eligible for a potential research and development milestone payment of up to 57.5 million pounds in the future.
Nanna focuses on addressing the high medical needs of age-related diseases, including mitochondrial-related diseases.
the company's exclusive holding of an advanced screening platform based on new DNA coding chemical library (DELs) technology, unlike traditional DELs, which enables phenotype-based screening and can be applied to a variety of analytical systems, such as cell-based analysis using patient-derived cells, making it possible to biologically screen drug candidate syfusis for specific diseases.
this advanced platform will greatly assist Astaire in early drug development, helping it create a more diverse portfolio of compounds and rapid screening.
Nanna screening platform vs. traditional drug screening platform, Dr. Kenji Yasukawa, President and CEO of Nanna's official website, said, "I believe this acquisition will enable Nanna's unique technology platform to combine our research and development capabilities for mitochondrial-related diseases to propose new solutions to address unmet medical needs."
Nanna's platform will accelerate astellas' drug development in the field of mitochondria-related biology. "We are committed to the development of new mitochondrial regulators," said Dr. David Williams, chief executive of
.
mitochondria, a vital organ, is the center of energy generation and signaling in almost every cell, associated with many diseases.
we are delighted to be a member of Astellas, a pharmaceutical company with a legacy of mitochondrial biology research and development, and we will do our best to help build on these findings."
" Reference source: Astellas Announces Acquisition of Nanna -Nanna's unique screening platform has great the project to create novels, leader to maximization of mitochondria-related research.